ArticleExperimental and therapeutic medicine2018
Silencing FOXC1 inhibits growth and migration of human oral squamous cell carcinoma cells.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Active chromatin marks and up-regulation of FOXC1 in uterine epithelial cells demarcate the onset of reproductive decline in aging females.NAR molecular medicine · 2025Article
- Down-regulated expression of miR-582 predicts poor prognosis and facilitates melanoma progression by targeting FOXC1.Archives of dermatological research · 2022Article
- FOXC1‑mediated TRIM22 regulates the excessive proliferation and inflammation of fibroblast‑like synoviocytes in rheumatoid arthritis via NF‑κB signaling pathway.Molecular medicine reports · 2022Article
- Long Non-Coding RNA LINC01929 Accelerates Progression of Oral Squamous Cell Carcinoma by Targeting the miR-137-3p/FOXC1 Axis.Frontiers in oncology · 2021Article
- Forkhead Box C1 (FOXC1) Expression in Stromal Cells within the Microenvironment of T and NK Cell Lymphomas: Association with Tumor Dormancy and Activation.Cancer research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forkhead box C1 (FOXC1) is a transcription factor that serves an important role in regulating tumorigenesis and cancer progression. However, the expression and functional role of FOXC1 in oral squamous cell carcinoma (OSCC) remains unclear. FOXC1 protein expression was determined using immunohistochemical staining of OSCC tissues and normal tissues. Cell Counting Kit-8, colony formation, migration and 5-ethynyl-2'-deoxyuridine assays were performed to investigate the role and underlying mechanism of action of FOXC1 in OSCC. A consistent increase in the immunoreactive intensity of FOXC1 in OSCC tissues as compared with that in adjacent normal tissues was demonstrated. Knockdown of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.